Mar 14, 2018 4:00 pm EDT Capricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate Update
Mar 08, 2018 4:00 pm EST Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on Wednesday, March 14
Feb 22, 2018 1:23 pm EST New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy
Feb 12, 2018 8:00 am EST Capricor to Give Update on HOPE-2 Clinical Trial for CAP-1002 at International Conference on Duchenne Muscular Dystrophy
Feb 05, 2018 11:11 am EST Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy
Jan 16, 2018 7:00 am EST Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies
Dec 13, 2017 8:00 am EST Capricor Therapeutics Announces Issuance of Key U.S. Patent on Exosome Technology
Nov 29, 2017 7:00 am EST Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002